Skip to main content

Liver Cancer Clinical Trials

Review the liver cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 101-125 of 159

Pomalidomide and Nivolumab for the Treatment of Virus-Associated Malignancies with or without HIV
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
A Study of MGC026 in Participants With Advanced Solid Tumors
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
FLC Peptide Vaccine Combined with Nivolumab and Ipilimumab for the Treatment of Patients with Fibrolamellar Cancer
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Semaglutide and Standard of Care Chemotherapy for The Treatment of Metastatic or Unresectable Pancreatic, Colorectal, or Hepatocellular Cancer
Status: Active
Location: Banner University Medical Center - Tucson, Tucson, Arizona
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Status: Active
Location: See ClinicalTrials.gov
A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma
Status: Active
Location: See ClinicalTrials.gov
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
Status: Active
Location: See ClinicalTrials.gov
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor
Status: Active
Location: See ClinicalTrials.gov
A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
A Study of HB0045 Injection in Patients With Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Status: Active
Location: See ClinicalTrials.gov
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
Status: Active
Location: UT MD Anderson Cancer Center, Houston, Texas
Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC)
Status: Active
Location: See ClinicalTrials.gov
Maintenance Zanzalintinib and Durvalumab for the Treatment of Metastatic or Unresectable Hepatocellular Cancer after Induction Tremelimumab and Durvalumab
Status: Approved
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Cell Therapy (Tumor Infiltrating Lymphocytes) and Aldesleukin in Treating Patients with Locally Advanced, Recurrent, Refractory, or Metastatic Biliary Tract Cancers
Status: Temporarily Closed to Accrual
Location: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma
Status: Temporarily Closed to Accrual
Location: 21 locations
Atezolizumab in Combination with Cyclophosphamide, Sorafenib, and Bevacizumab for the Treatment of Recurrent or Refractory Solid Tumors in Pediatric Patients, ANGIO-A Study
Status: Temporarily Closed to Accrual
Location: 2 locations
Y-90 SIRT and SBRT for the Treatment of Unresectable Liver Cancer
Status: Temporarily Closed to Accrual
Location: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma
Status: Temporarily Closed to Accrual
Location: Roswell Park Cancer Institute, Buffalo, New York
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor with Liver Metastatic Disease
Status: Temporarily Closed to Accrual
Location: 2 locations